Abdera Therapeutics
NEWS
Pharmaceutical companies are combining antibodies with radioisotopes in a bid to more precisely deliver radiation to cancers and tumors.
Rapport Therapeutics tops this year’s list with $250 million in Series A and B financing in just six months.
Abdera Therapeutics will use the money to fund its ROVEr platform and advance its lead asset ABD-147 for small-cell lung cancer.
IN THE PRESS
JOBS